AgomAb Therapeutics NV
corporate_fare Company Profile
AgomAb Therapeutics NV (NASDAQ:AGMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for AGMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for AGMB spans 6-K, 20-F, SCHEDULE 13D, 424B4.
Recent high-impact activity:
- Agomab's Ontunisertib Shows 3% Event Rate in Crohn's Fibrosis Extension Study
- Agomab's Lung Drug Shows >50% Target Reduction in Phase 1, Paving Way for Phase 2
- Agomab Reports Positive Phase 1 Data for AGMB-447 in IPF; Phase 2 INSPIRIA Study to Start H2 2026
- Agomab Reports Half-Year 2026 Financials, Confirms Outlook, and Extends Cash Runway into 2029
- Agomab Posts EUR252M Cash, Confirms 2026 Outlook with Key Catalysts Ahead
Financial Snapshot
Short Interest & Short Volume
4.60 days to coverFINRA reported short interest of 867,701 shares in AGMB as of the September 15, 2026 settlement, a 1.2% decrease from the prior period — about 4.6 days to cover at its recent average daily volume. On October 2, 2026, 66.7% of AGMB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
AGMB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.